Company intelligence / Profile preview

Genzyme, a Sanofi Company

Cambridge, Massachusetts, USAsanofi.com ↗

Ownership: Private
Employees: ~10000
Development stage: Commercial

Overview

Genzyme (now Sanofi's Specialty Care division) has successful commercial therapies for multiple rare genetic diseases including Gaucher, Fabry, and Pompe disease, as well as marketed therapies for multiple sclerosis and oncology. Notable products include enzyme replacement therapies (Cerezyme, Fabrazyme, Myozyme), alemtuzumab (for MS), and dupilumab (for inflammatory diseases). Clinical pipeline integrated under Sanofi includes active programs across immunology, oncology, neurology, and rare diseases, with dozens of assets in all clinical stages[2][4][7].

Therapeutic areas: ImmunologyRare DiseasesHematologyOncologyNeurology
Modalities: Enzyme replacement therapyBiologicSmall moleculeMonoclonal antibodyCell therapy
Industry: Pharma

Partnerships

Regeneron

Beyond the preview

Go deeper on Genzyme, a Sanofi Company.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genzyme, a Sanofi Company.

Explore the full profile